PHARMACOLOGY OF AQUEOUS OUTFLOW IN THE EYE
眼房水流出的药理学
基本信息
- 批准号:2161438
- 负责人:
- 金额:$ 24.32万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1989
- 资助国家:美国
- 起止时间:1989-04-01 至 1996-03-31
- 项目状态:已结题
- 来源:
- 关键词:Animalia adrenergic agents anterior chamber biological models cholinergic agents cyclic AMP drug receptors epinephrine eye pharmacology glaucoma human tissue intraocular aqueous flow ocular hypotensive perfusion phosphorylation physiology protein kinase receptor sensitivity sclera second messengers trabecular meshwork
项目摘要
DESCRIPTION (Investigator's Abstract): The overall goal of proposed
research is to gain further knowledge of the physiology and pharmacology of
aqueous outflow in the human eye.In proposed studies, the investigators
have chosen to look at two general classes of drugs used therapeutically in
the treatment of glaucoma; adrenergic agents and cholinergic agents. The
specific aims are to characterize outflow facility responses to these drugs
in her recently described human isolated outflow pathway perfusion model,
to map the distribution of drug receptors in outflow tissues, and to
characterize relevant second messenger systems. This three-pronged
approach, coordinating studies in physiology, biochemistry, and molecular
biology, has the potential for producing a wealth of information greater
than the sum of each individual approach in isolation. Recent refinements
in molecular biology techniques and their applications is revolutionizing
the diagnosis and treatment of disease, as well as basic medical research.
The investigator's hope that her approach, using this powerful new
technology in conjunction with the human TM model will allow her to develop
a composite map of the human outflow system which will localize groups of
cells which mediate changes in outflow resistance and characterize the
second messenger systems which are coupled to these changes. Enhanced
understanding of the basic mechanism(s) underlying normal outflow
physiology may lend new insight into the pathogenesis of primary open angle
glaucoma, and probably will facilitate the development of more effective,
specific, and safe antiglaucoma drugs.
描述(研究者的摘要):提议的总体目标
研究的目的是为了获得更多的生理学和药理学知识
人眼中的房水流出。在拟议的研究中,研究人员
选择研究两种一般类别的治疗药物
青光眼的治疗;肾上腺素能药物和胆碱能药物。 这
具体目标是描述流出设施对这些药物的反应
在她最近描述的人体隔离流出通路灌注模型中,
绘制流出组织中药物受体的分布图,并
描述相关第二信使系统的特征。这个三管齐下
方法,协调生理学、生物化学和分子研究
生物学具有产生大量信息的潜力
而不是孤立地使用每个单独方法的总和。 最近的改进
分子生物学技术及其应用正在发生革命性的变化
疾病的诊断和治疗以及基础医学研究。
调查员希望她的方法能够利用这种强大的新方法
技术与人类 TM 模型相结合将使她能够开发
人口流出系统的综合地图,将定位人群
介导流出阻力变化并表征的细胞
与这些变化耦合的第二信使系统。 增强型
了解正常流出的基本机制
生理学可能为原发性开角的发病机制提供新的见解
青光眼,并且可能会促进更有效的开发,
特异性、安全的抗青光眼药物。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KRISTINE A ERICKSON其他文献
KRISTINE A ERICKSON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KRISTINE A ERICKSON', 18)}}的其他基金
THE PHARMACOLOGY OF AQUEOUS OUTFLOW IN THE HUMAN EYE
人眼房水流出的药理学
- 批准号:
3264191 - 财政年份:1989
- 资助金额:
$ 24.32万 - 项目类别:
PERFUSED TRABECULAR MESHWORK AS A MODEL FOR OUTFLOW
灌注小梁网作为流出模型
- 批准号:
3264187 - 财政年份:1989
- 资助金额:
$ 24.32万 - 项目类别:
PERFUSED TRABECULAR MESHWORK AS A MODEL FOR OUTFLOW
灌注小梁网作为流出模型
- 批准号:
3264189 - 财政年份:1989
- 资助金额:
$ 24.32万 - 项目类别:
PERFUSED TRABECULAR MESHWORK AS A MODEL FOR OUTFLOW
灌注小梁网作为流出模型
- 批准号:
3264190 - 财政年份:1989
- 资助金额:
$ 24.32万 - 项目类别:
相似海外基金
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8358448 - 财政年份:2012
- 资助金额:
$ 24.32万 - 项目类别:
Preclinical test for the efficacy of adrenergic agents in treatment of AD
肾上腺素能药物治疗AD疗效的临床前试验
- 批准号:
8517552 - 财政年份:2012
- 资助金额:
$ 24.32万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7952159 - 财政年份:2009
- 资助金额:
$ 24.32万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7952152 - 财政年份:2009
- 资助金额:
$ 24.32万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7719194 - 财政年份:2008
- 资助金额:
$ 24.32万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7605416 - 财政年份:2007
- 资助金额:
$ 24.32万 - 项目类别:
MODULATING FLUID THERAPY WITH ADRENERGIC AGENTS AND CYCLIC AMP ENHANCERS IN
使用肾上腺素能药物和环放大器增强剂调节液体治疗
- 批准号:
7605425 - 财政年份:2007
- 资助金额:
$ 24.32万 - 项目类别:
THE EFFECT OF BETA-ADRENERGIC AGENTS AND FLUID THERAPY IN HUMANS
β-肾上腺素能药物和液体疗法对人体的影响
- 批准号:
7378753 - 财政年份:2006
- 资助金额:
$ 24.32万 - 项目类别:
Adrenergic Agents for Methamphetamine: Outpatient Trials
甲基苯丙胺肾上腺素药物:门诊试验
- 批准号:
6825160 - 财政年份:2004
- 资助金额:
$ 24.32万 - 项目类别:
ADRENERGIC AGENTS FOR CARDIOPULMONARY RESUSCITATION
用于心肺复苏的肾上腺素能药物
- 批准号:
2702283 - 财政年份:1997
- 资助金额:
$ 24.32万 - 项目类别:














{{item.name}}会员




